- Previous Close
557.92 - Open
556.68 - Bid 541.44 x 900
- Ask --
- Day's Range
550.15 - 559.56 - 52 Week Range
437.26 - 627.88 - Volume
815,100 - Avg. Volume
1,223,403 - Market Cap (intraday)
212.467B - Beta (5Y Monthly) 0.78
- PE Ratio (TTM)
34.85 - EPS (TTM)
15.94 - Earnings Date Jan 31, 2025 - Feb 5, 2025
- Forward Dividend & Yield 1.56 (0.28%)
- Ex-Dividend Date Sep 13, 2024
- 1y Target Est
657.43
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
www.thermofisher.com122,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: TMO
View More
Performance Overview: TMO
Trailing total returns as of 11/4/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TMO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TMO
View MoreValuation Measures
Market Cap
212.47B
Enterprise Value
241.14B
Trailing P/E
34.83
Forward P/E
23.42
PEG Ratio (5yr expected)
2.09
Price/Sales (ttm)
5.04
Price/Book (mrq)
4.34
Enterprise Value/Revenue
5.69
Enterprise Value/EBITDA
20.96
Financial Highlights
Profitability and Income Statement
Profit Margin
14.48%
Return on Assets (ttm)
4.71%
Return on Equity (ttm)
12.94%
Revenue (ttm)
42.37B
Net Income Avi to Common (ttm)
6.14B
Diluted EPS (ttm)
15.94
Balance Sheet and Cash Flow
Total Cash (mrq)
6.65B
Total Debt/Equity (mrq)
72.33%
Levered Free Cash Flow (ttm)
6.82B
Research Analysis: TMO
View MoreCompany Insights: TMO
TMO does not have Company Insights
Research Reports: TMO
View MoreThermo Fisher Sees Demand Slowly Return
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (22%); and lab products and services, which includes CRO services (54%).
RatingPrice TargetThermo Fisher Earnings: Modest Improvement in Demand, Revenue Growth Return Imminent
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of end-2023 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (10%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
RatingPrice TargetInsider-sentiment data from Vickers Stock Research reflects nice relative
Insider-sentiment data from Vickers Stock Research reflects nice relative improvement this week, with the caveat that transaction volume is cyclically low as corporate insiders are currently broadly prohibited from trading due to earnings season. Even so, the one-week sell/buy ratios from Vickers are all in the lower (positive) zone of the neutral range after having spent the past few weeks in the middle to upper range of that same neutral zone. That has led to either slight improvement or at least a plateauing in the eight-week sell/buy readings, all of which are squarely in the middle of the neutral range. And with all the issues in play right now (the U.S. election, the Middle East, the Fed's next move, the behavior of Treasury yields, the ultimate quality of the current earnings season, etc.), neutral seems to be a reasonable posture to take at the moment. On a sector basis, insider selling outpaced buying in the Consumer Discretionary sector, with shares valued at roughly $63 million sold versus less than $5 million bought. Selling by insiders was also evident in the Financial sector, with shares valued at $42 million sold versus less than $3 million bought, as well as in the Industrial sector, with $33 million sold versus $1 million bought. This week, analysts at Vickers highlighted insider transactions of interest at PBF Energy Inc. (NYSE: PBF) and Philip Morris International Inc. (NYSE: PM).
Thermo Fisher Earnings: Modest Improvement in Demand, Revenue Growth Return Imminent
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of end-2023 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (10%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
RatingPrice Target